Full-Time

Director – Global Real-world Evidence

Rwe, Global Commercial Strategy Organization, Gcso

Posted on 6/1/2026

Deadline 6/21/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$164k - $282.9k/yr

Bridgewater Township, NJ, USA

In Person

Up to 15% travel.

Category
Biology & Biotech (2)
,
Required Skills
Python
SAS
R
biostatistics
Requirements
  • Master’s degree in a quantitative field (e.g., epidemiology, HEOR, pharmacoepidemiology, biostatistics); PhD preferred
  • Minimum of 6 years of relevant experience in pharma, biotech, or healthcare consulting
  • Demonstrated expertise in observational research (prospective and retrospective) across study design, conduct, analysis, and reporting
  • Experience executing real-world evidence studies using diverse real-world data sources; multi-country real-world evidence experience preferred
  • Proficiency in standard office applications (Word, Excel, PowerPoint) and familiarity with statistical programming tools (SAS, R, Python)
  • Strong communication, storytelling, and presentation skills, with ability to translate complex methods and statistics for both technical and non-technical stakeholders
  • Highly motivated, intellectually curious, and skilled at managing multiple priorities in a fast-paced environment
  • Proven experience working effectively in a matrixed, cross-functional team environment
  • The position is based in Raritan, New Jersey and will require up to 15% travel
Responsibilities
  • Leading the global real-world evidence strategy and execution for key oncology assets, including define research questions, develop study protocols, study design/methodology, real-world data selection and analysis, results dissemination, and communication to support medical adoption and product differentiation across regions
  • Serve as the GRWE representative on cross-functional franchise teams, partnering closely with Global Medical Affairs, Market Access, and other stakeholders. Act as the RWE subject matter expert in Global Integrated Evidence Generation Plan (IEG) and oversee global real-world data and evidence generation strategies
  • Advance RWE capabilities and best practices by sharing latest development and guidance in RWE, delivering technical training, strengthening internal expertise in advanced RWE methods, and supporting governance, quality standards, and compliance for global and local RWE activities
  • Lead Evidence Lab coordination to drive concept development, stakeholder alignment, and prioritization of RWE opportunities within the Global IEGP process
  • Ensure full compliance with regulatory, legal, and commercial regulations in research conduct, data usage, and scientific communication
Desired Qualifications
  • Experience in oncology therapy area
  • Experience with programming in major statistical analysis systems
  • Good understanding of evidence-based medicine and comparative effectiveness analyses in healthcare research
  • Experience of managing analytical/statistical activities with external service providers
  • Understanding of global healthcare delivery, reimbursement, and payer dynamics desirable

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI, DARZALEX, and RYBREVANT drive oncology growth despite STELARA erosion.
  • Abu Dhabi’s intelligent OR network accelerates surgical AI data generation and validation.
  • Atraverse and New Jersey Innovation Hub strengthen J&J’s cardiac access and startup sourcing.

What critics are saying

  • STELARA biosimilar erosion keeps crushing immunology revenue and pressures 2026 guidance.
  • Intuitive Surgical and Boston Scientific can outbundle J&J’s open surgery software stack.
  • Rapid MedTech innovation cycles make Shockwave and VARIPULSE vulnerable to faster rival iteration.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech across oncology, immunology, and surgery.
  • Polyphonic links AWS and NVIDIA into an open surgical intelligence ecosystem.
  • Shockwave and VARIPULSE give J&J leading platforms in coronary and electrophysiology procedures.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-10%
Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.